The expression, function and targeting of haem oxygenase-1 in cancer

Current Cancer Drug Targets

Volumn 14, Issue 4, 2014, Pages 337-347

  Hjortsø, Mads Duus ^a   Andersen, Mads Hald ^a  

^a Mental Health Services CPH   (Denmark)

Author keywords

Cancer; Haem oxygenase 1; Regulatory T cells; Tumour immunology; Zinc protoporphyrin

Indexed keywords

1, 3 DIOXOLANE; CISPLATIN; DOXORUBICIN; GELATINASE B; HEME OXYGENASE 1; IMATINIB; IMIDAZOLE; IPILIMUMAB; METALLOPORPHYRIN; PROTOPORPHYRIN; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; ENZYME INHIBITOR; HMOX1 PROTEIN, HUMAN; TUMOR PROTEIN;

ANGIOGENESIS; APOPTOSIS; ARTICLE; AUTOIMMUNITY; CELL PROTECTION; ENZYME ACTIVITY; GROWTH DISORDER; HUMAN; IMMUNOREGULATION; INFLAMMATION; NEOPLASM; NONHUMAN; OXIDATIVE STRESS; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TUMOR GROWTH; TUMOR MICROENVIRONMENT; ANIMAL; ANTAGONISTS AND INHIBITORS; ANTIGEN PRESENTING CELL; DRUG EFFECTS; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; METABOLISM; MOLECULARLY TARGETED THERAPY; NEOPLASMS; REGULATORY T LYMPHOCYTE;

ANIMALS; ANTIGEN-PRESENTING CELLS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG RESISTANCE, NEOPLASM; ENZYME INHIBITORS; GENE EXPRESSION REGULATION, NEOPLASTIC; HEME OXYGENASE-1; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASM PROTEINS; NEOPLASMS; T-LYMPHOCYTES, REGULATORY; TUMOR MICROENVIRONMENT;

EID: 84903737201     PISSN: 15680096     EISSN: 18735576     Source Type: Journal    
DOI: 10.2174/1568009614666140320111306     Document Type: Article

References (125)

1. Hanahan, D.; Weinberg, R. A.; Francisco, S. The hallmarks of cancer. Cell 2000, 100, 57-70.
2. Hanahan, D.; Weinberg, R. A. Hallmarks of cancer: the next generation. Cell 2011, 144, 646-674.
3. Mantovani, A.; Allavena, P.; Sica, A.; Balkwill, F. Cancer-related inflammation. Nature 2008, 454, 436-444.
4. Karin, M. Nuclear factor-kappaB in cancer development and progression. Nature 2006, 441, 431-436.
5. Fuchs-Tarlovsky, V. Role of antioxidants in cancer therapy. Nutrition 2013, 29, 15-21.
6. Tenhunen, R.; Marver, H. S.; Schmid, R. The enzymatic conversion of heme to bilirubin by microsomal heme oxygenase. Proc. Natl. Acad. Sci. U. S. A. 1968, 61, 748.
7. Hwang, H.-W.; Lee, J.-R.; Chou, K.-Y.; Suen, C.-S.; Hwang, M.-J.; Chen, C.; Shieh, R.-C.; Chau, L.-Y. Oligomerization is crucial for the stability and function of heme oxygenase-1 in the endoplasmic reticulum. J. Biol. Chem. 2009, 284, 22672-22679.
8. Keyse, S. M.; Tyrrell, R. M. Heme oxygenase is the major 32-kDa stress protein induced in human skin fibroblasts by UVA radiation, hydrogen peroxide, and sodium arsenite. Proc. Natl. Acad. Sci. U. S. A. 1989, 86, 99-103.
9. Motterlini, R.; Foresti, R.; Bassi, R.; Calabrese, V.; Clark, J. E.; Green, C. J.; Chem, R. J. B. Endothelial heme oxygenase-1 induction by hypoxia-Modulation by inducible nitric-oxide synthase. J. Biol. Chem. 2000, 275, 13613-13620.
10. Terry, C. M.; Clikeman, J. A.; Hoidal, J. R.; Callahan, K. S.; Christi, M.; John, R. Effect of tumor necrosis factor-α and interleukin-1 α on heme oxygenase-1 expression in human endothelial cells. Am. J. Hear. Circ. Physiol. 1998, 274, H883-H891.
11. Kongpetch, S.; Kukongviriyapan, V.; Prawan, A.; Senggunprai, L.; Kukongviriyapan, U.; Buranrat, B. Crucial role of heme oxygenase-1 on the sensitivity of cholangiocarcinoma cells to chemotherapeutic agents. PLoS One 2012, 7, e34994.
12. Banerjee, P.; Basu, A.; Wegiel, B.; Otterbein, L. E.; Mizumura, K.; Gasser, M.; Waaga-Gasser, A. M.; Choi, A. M.; Pal, S. Heme oxygenase-1 promotes survival of renal cancer cells through modulation of apoptosis-& autophagy-regulating molecules. J. Biol. Chem. 2012, 287, 32113-32123.
13. Zhang, W.; Qiao, T.; Zha, L. Inhibition of heme oxygenase-1 enhances the radiosensitivity in human non small cell lung cancer a549 cells. Cancer Biother. Radiopharm. 2011, 26, 639-645.
14. Kapturczak, M. H.; Wasserfall, C.; Brusko, T.; Campbellthompson, M.; Ellis, T. M.; Atkinson, M. A.; Agarwal, A. Heme oxygenase-1modulates early inflammatory responses: Evidence from the heme oxygenase-1-deficient mouse. Am. J. Pathol. 2004, 165, 1045-1053.
15. Jozkowicz, A.; Was, H.; Dulak, J. Heme oxygenase-1 in tumors: is it a false friend. Antioxid. Redox Signal. 2007, 9, 2099-2118.
16. Maines, M. D.; Trakshel, G. M.; Kutty, R. K.; Maine, M. D. Characterization of two constitutive forms of rat liver microsomal heme oxygenase only one molecular species is inducible. J. Biol. Chem. 1986, 261, 411-419.
17. Hayashi, S.; Omata, Y.; Sakamoto, H.; Higashimoto, Y.; Hara, T.; Sagara, Y.; Noguchi, M. Characterization of rat heme oxygenase-3 gene. Implication of processed pseudogenes derived from heme oxygenase-2 gene. Gene 2004, 336, 241-250.
18. Camara, N. O. S.; Soares, M. P. Heme oxygenase-1 (HO-1), a protective gene that prevents chronic graft dysfunction. Free Radic. Biol. Med. 2005, 38, 426-435.
19. Poss, K. D.; Tonegawa, S. Reduced stress defense in heme oxygenase 1-deficient cells. Proc. Natl. Acad. Sci. U. S. A. 1997, 94, 10925-10930.
20. Su, Z.; Shu, L.; Khor, T. O.; Lee, J. H.; Fuentes, F.; Kong, A. T. A perspective on dietary phytochemicals and cancer chemoprevention: oxidative stress, Nrf2 and epigenomics. Top Curr. Chem. 2013, 329, 133-162.
21. Fang, J.; Seki, T.; Maeda, H. Therapeutic strategies by modulating oxygen stress in cancer and inflammation. Adv. Drug Deliv. Rev. 2009, 61, 290-302.
22. Jian, Z.; Li, K.; Liu, L.; Zhang, Y.; Zhou, Z.; Li, C.; Gao, T. Heme oxygenase-1 protects human melanocytes from H2O2-induced oxidative stress via the Nrf2-ARE pathway. J. Invest. Dermatol. 2011, 131, 1420-1427.
23. Minetti, M.; Mallozzi, C.; Di Stasi, A. M.; Pietraforte, D. Bilirubin is an effective antioxidant of peroxynitrite-mediated protein oxidation in human blood plasma. Arch. Biochem. Biophys. 1998, 352, 165-174.
24. Jansen, T.; Hortmann, M.; Oelze, M.; Opitz, B.; Steven, S.; Schell, R.; Knorr, M.; Karbach, S.; Schuhmacher, S.; Wenzel, P.; Münzel, T.; Daiber, A. Conversion of biliverdin to bilirubin by biliverdin reductase contributes to endothelial cell protection by heme oxygenase-1-evidence for direct and indirect antioxidant actions of bilirubin. J. Mol. Cell. Cardiol. 2010, 49, 186-195.
25. Nuhn, P.; Künzli, B. M.; Hennig, R.; Mitkus, T.; Ramanauskas, T.; Nobiling, R.; Meuer, S. C.; Friess, H.; Berberat, P. O. Heme oxygenase-1 and its metabolites affect pancreatic tumor growth in vivo. Mol. Cancer 2009, 8, 37.
26. Busserolles, J.; Megías, J.; Terencio, M. C.; Alcaraz, M. J. Heme oxygenase-1 inhibits apoptosis in Caco-2 cells via activation of Akt pathway. Int. J. Biochem. Cell Biol. 2006, 38, 1510-1517.
27. Petrache, I.; Otterbein, L. E. O. E.; Alam, J.; Wiegand, G. W.; Augustine, M. K.; Choi, A. M. K. Heme oxygenase-1 inhibits TNF-α-induced apoptosis in cultured fibroblasts. Am. J. Physiol. lung cell Mol. Physiol. 2000, 278, 312-319.
28. Wang, X.; Wang, Y.; Kim, H. P.; Nakahira, K.; Ryter, S. W.; Choi, A. M. K. Carbon monoxide protects against hyperoxia-induced endothelial cell apoptosis by inhibiting reactive oxygen species formation. J. Biol. Chem. 2007, 282, 1718-1726.
29. Halliwell, B.; Gutteridge, J. M. C. Oxygen toxicity, oxygen radicals, transition metals and disease. Biochem. J. 1984, 219, 1-14.
30. Cermak, J.; Balla, J. J.; Jacob, H. S.; Enright, H.; Nath, K.; Vercellotti, G. M. Tumor cell heme uptake induces ferritin synthesis resulting in altered oxidant sensitivity: Possible role in chemotherapy efficacy. Cancer Res. 1993, 53, 5308-5313.
31. Jeon, W.-K.; Hong, H.-Y.; Seo, W.-C.; Lim, K.-H.; Lee, H.-Y.; Kim, W.-J.; Song, S.-Y.; Kim, B.-C. Smad7 sensitizes A549 lung cancer cells to cisplatin-induced apoptosis through heme oxygenase-1 inhibition. Biochem. Biophys. Res. Commun. 2012, 420, 288-292.
32. Maines, M. D.; Abrahamsson, P. A. Expression of heme oxygenase-1 (HSP32) in human prostate: normal, hyperplastic, and tumor tissue distribution. Urology 1996, 47, 727-733.
33. Gleixner, K. V.; Mayerhofer, M.; Vales, A.; Gruze, A.; Hörmann, G.; Cerny-Reiterer, S.; Lackner, E.; Hadzijusufovic, E.; Herrmann, H.; Iyer, A. K.; Krauth, M.-T.; Pickl, W. F.; Marian, B.; Panzer-Grümayer, R.; Sillaber, C.; Maeda, H.; Zielinski, C.; Valent, P. Targeting of Hsp32 in solid tumors and leukemias: a novel approach to optimize anticancer therapy. Curr. Cancer Drug Targets 2009, 9, 675-689.
34. Yin, Y.; Liu, Q.; Wang, B.; Chen, G.; Xu, L.; Zhou, H. Expression and function of heme oxygenase-1 in human gastric cancer. Exp. Biol. Med. 2012, 237, 362-371.
35. Becker, J. C.; Fukui, H.; Imai, Y.; Sekikawa, A.; Kimura, T.; Yamagishi, H.; Yoshitake, N.; Pohle, T.; Domschke, W.; Fujimori, T. Colonic expression of heme oxygenase-1 is associated with a better long-term survival in patients with colorectal cancer. Scand. J. Gastroenterol. 2007, 42, 852-858.
36. Berberat, P. O.; Dambrauskas, Z.; Gulbinas, A.; Giese, T.; Giese, N.; Künzli, B.; Autschbach, F.; Meuer, S.; Büchler, M. W.; Friess, H. Inhibition of heme oxygenase-1 increases responsiveness of pancreatic cancer cells to anticancer treatment. Clin. Cancer Res. 2005, 11, 3790-3798.
37. Flad, T.; Mueller, L.; Dihazi, H.; Grigorova, V.; Bogumil, R.; Beck, A.; Thedieck, C.; Mueller, G. A.; Kalbacher, H.; Mueller, C. A. T cell epitope definition by differential mass spectrometry: identification of a novel, immunogenic HLA-B8 ligand directly from renal cancer tissue. Proteomics 2006, 6, 364-374.
38. Mayerhofer, M.; Gleixner, K. V; Mayerhofer, J.; Hoermann, G.; Jaeger, E.; Aichberger, K. J.; Ott, R. G.; Greish, K.; Nakamura, H.; Derdak, S.; Samorapoompichit, P.; Pickl, W. F.; Sexl, V.; Esterbauer, H.; Schwarzinger, I.; Sillaber, C.; Maeda, H.; Valent, P. Targeting of heat shock protein 32 (Hsp32)/ heme oxygenase-1 (HO-1) in leukemic cells in chronic myeloid leukemia: a novel approach to overcome resistance against imatinib. Blood 2008, 111, 2200-2210.
39. Okamoto, I.; Krögler, J.; Endler, G.; Kaufmann, S.; Mustafa, S.; Exner, M.; Mannhalter, C.; Wagner, O.; Pehamberger, H. A microsatellite polymorphism in the heme oxygenase-1 gene promoter is associated with risk for melanoma. Int. J. Cancer 2006, 119, 1312-1315.
40. Oh, G.-S.; Pae, H.-O.; Choi, B.-M.; Chae, S.-C.; Lee, H.-S.; Ryu, D.-G.; Chung, H.-T. 3-Hydroxyanthranilic acid, one of metabolites of tryptophan via indoleamine 2,3-dioxygenase pathway, suppresses inducible nitric oxide synthase expression by enhancing heme oxygenase-1 expression. Biochem. Biophys. Res. Commun. 2004, 320, 1156-1162.
41. Lee, P. J.; Jiang, B.-H.; Chin, B. Y.; Iyer, N. V; Alam, J.; Semenza, G. L.; Choi, A. M. K. Hypoxia-inducible factor-1 mediates transcriptional activation of the heme oxygenase-1 gene in response to hypoxia. J. Biol. Chem. 1997, 272, 5375-5381.
42. Li, B.; Takeda, K.; Yokoyama, S.; Shibahara, S. A prolylhydroxylase inhibitor, ethyl-3,4-dihydroxybenzoate, induces haem oxygenase-1 expression in human cells through a mechanism independent of hypoxia-inducible factor-1alpha. J. Biochem. 2008, 144, 643-654.
43. Zhang, D. D.; Hannink, M. Distinct cysteine residues in keap1 are required for keap1-dependent ubiquitination of Nrf2 and for stabilization of Nrf2 by chemopreventive agents and oxidative stress. Mol. Cell. Biol. 2003, 23, 8137-8151.
44. Shibata, T.; Ohta, T.; Tong, K. I.; Odogawa, R.; Tsuta, K.; Asamura, H. Cancer related mutations in NRF2 impair its recognition by Keap1-Cul3 E3 ligase and promote malignancy. Proc. Natl. Acad. Sci. 2008, 106, 10392-10393.
45. Shelton, P.; Jaiswal, A. K. The transcription factor NF-E2-related factor 2 (Nrf2): a protooncogene? FASEB J. 2013, 27, 414-423.
46. Konstantinopoulos, P. A; Spentzos, D.; Fountzilas, E.; Francoeur, N.; Sanisetty, S.; Grammatikos, A. P.; Hecht, J. L.; Cannistra, S. A. Keap1 mutations and Nrf2 pathway activation in epithelial ovarian cancer. Cancer Res. 2011, 71, 5081-5089.
47. Desmard, M.; Boczkowski, J.; Poderoso, J.; Motterlini, R. Mitochondrial and cellular heme-dependent proteins as targets for the bioactive function of the heme oxygenase/carbon monoxide system. Antioxid. Redox Signal. 2007, 9, 2139-2155.
48. Wegiel, B.; Gallo, D.; Csizmadia, E.; Harris, C.; Belcher, J.; Vercellotti, G. M.; Penacho, N.; Seth, P.; Sukhatme, V.; Ahmed, A.; Pandolfi, P. P.; Helczynski, L.; Bjartell, A.; Persson, J. L.; Otterbein, L. E. Carbon monoxide expedites metabolic exhaustion to inhibit tumor growth. Cancer Res. 2013, 73, 7009-7021.
49. Vítek, L.; Gbelcová, H.; Muchová, L.; Váňová, K.; Zelenka, J.; Koníčková, R.; Suk, J.; Zadinova, M.; Knejzlík, Z.; Ahmad, S.; Fujisawa, T.; Ahmed, A.; Ruml, T. Antiproliferative effects of carbon monoxide on pancreatic cancer. Dig. Liver Dis. 2014.
50. Tauber, S.; Jais, A.; Jeitler, M.; Haider, S.; Husa, J.; Lindroos, J.; Knöfler, M.; Mayerhofer, M.; Pehamberger, H.; Wagner, O.; Bilban, M. Transcriptome analysis of human cancer reveals a functional role of heme oxygenase-1 in tumor cell adhesion. Mol. Cancer 2010, 9, 200.
51. Zou, C.; Zhang, H.; Li, Q.; Xiao, H.; Yu, L.; Ke, S.; Zhou, L.; Liu, W.; Wang, W.; Huang, H.; Ma, N.; Liu, Q.; Wang, X.; Zhao, W.; Zhou, H.; Gao, X. Heme oxygenase-1: a molecular brake on hepatocellular carcinoma cell migration. Carcinogenesis 2011, 32, 1840-1848.
52. Hill, M.; Pereira, V.; Chauveau, C.; Zagani, R.; Remy, S.; Tesson, L.; Mazal, D.; Ubillos, L.; Brion, R.; Asghar, K.; Ashgar, K.; Mashreghi, M. F.; Kotsch, K.; Moffett, J.; Doebis, C.; Seifert, M.; Boczkowski, J.; Osinaga, E.; Anegon, I. Heme oxygenase-1 inhibits rat and human breast cancer cell proliferation: mutual cross inhibition with indoleamine 2,3-dioxygenase. FASEB J. 2005, 19, 1957-1968.
53. Lin, C.-W.; Shen, S.-C.; Hou, W.-C.; Yang, L.-Y.; Chen, Y.-C. Heme oxygenase-1 inhibits breast cancer invasion via suppressing the expression of matrix metalloproteinase-9. Mol. Cancer Ther. 2008, 7, 1195-1206.
54. Gueron, G.; De Siervi, A.; Ferrando, M.; Salierno, M.; De Luca, P.; Elguero, B.; Meiss, R.; Navone, N.; Vazquez, E. S. Critical role of endogenous heme oxygenase 1 as a tuner of the invasive potential of prostate cancer cells. Mol. Cancer Res. 2009, 7, 1745-1755.
55. Sacca, P.; Meiss, R.; Casas, G.; Mazza, O.; Calvo, J. C.; Navone, N.; Vazquez, E. Nuclear translocation of haeme oxygenase-1 is associated to prostate cancer. Br. J. Cancer 2007, 97, 1683-1689.
56. Lin, Q.; Weis, S.; Yang, G.; Weng, Y.-H.; Helston, R.; Rish, K.; Smith, A.; Bordner, J.; Polte, T.; Gaunitz, F.; Dennery, P. A. Heme oxygenase-1 protein localizes to the nucleus and activates transcription factors important in oxidative stress. J. Biol. Chem. 2007, 282, 20621-20633.
57. Liu, P.-L.; Tsai, J.-R.; Charles, A. L.; Hwang, J.-J.; Chou, S.-H.; Ping, Y.-H.; Lin, F.-Y.; Chen, Y.-L. Y.-H.; Hung, C.-Y.; Chen, W.-C.; Chong, I.-W. Resveratrol inhibits human lung adenocarcinoma cell metastasis by suppressing heme oxygenase 1-mediated nuclear factor-kappaB pathway and subsequently downregulating expression of matrix metalloproteinases. Mol. Nutr. Food Res. 2010, 54 Suppl 2, S196-204.
58. Józkowicz, A.; Liebert, M. A.; Huk, I.; Nigisch, A.; Weigel, G.; Dietrich, W.; Motterlini, R.; Dulak, J. Stimulation by carbon monoxide and inhibition by tin protoporphyrin-IX. Antioxid. Redox Signal. 2003, 5, 3-10.
59. Nishie, A.; Ono, M.; Shono, T. Macrophage infiltration and heme oxygenase-1 expression correlate with angiogenesis in human gliomas. Clin. cancer Res. 1999, 5, 1107-1113.
60. Ferrando, M.; Gueron, G.; Elguero, B.; Giudice, J.; Salles, A.; Leskow, F. C.; Jares-Erijman, E. A.; Colombo, L.; Meiss, R.; Navone, N.; De Siervi, A.; Vazquez, E. Heme oxygenase 1 (HO-1) challenges the angiogenic switch in prostate cancer. Angiogenesis 2011, 14, 467-479.
61. Shan, Y.; Pepe, J.; Lu, T. H.; Elbirt, K. K.; Lambrecht, R. W.; Bonkovsky, H. L. Induction of the heme oxygenase-1 gene by metalloporphyrins. Arch. Biochem. Biophys. 2000, 380, 219-227.
62. Sardana, M. K.; Kappas, A. Dual control mechanism for heme oxygenase: tin(IV)-protoporphyrin potently inhibits enzyme activity while markedly increasing content of enzyme protein in liver. Proc. Natl. Acad. Sci. U. S. A. 1987, 84, 2464-2468.
63. Nowis, D.; Bugajski, M.; Winiarska, M.; Bil, J.; Szokalska, A.; Salwa, P.; Issat, T.; Was, H.; Jozkowicz, A.; Dulak, J.; Stoklosa, T.; Golab, J. Zinc protoporphyrin IX, a heme oxygenase-1 inhibitor, demonstrates potent antitumor effects but is unable to potentiate antitumor effects of chemotherapeutics in mice. BMC Cancer 2008, 8, 197.
64. Fang, J.; Greish, K.; Qin, H.; Liao, L.; Nakamura, H.; Takeya, M.; Maeda, H. HSP32 (HO-1) inhibitor, copoly(styrene-maleic acid)-zinc protoporphyrin IX, a water-soluble micelle as anticancer agent: In vitro and in vivo anticancer effect. Eur. J. Pharm. Biopharm. 2012, 81, 540-547.
65. Metz, R.; Duhadaway, J. B.; Rust, S.; Munn, D. H.; Muller, A. J.; Mautino, M.; Prendergast, G. C. Zinc protoporphyrin IX stimulates tumor immunity by disrupting the immunosuppressive enzyme indoleamine 2,3-dioxygenase. Mol. Cancer Ther. 2010, 9, 1864-1871.
66. Sahoo, S. K.; Sawa, T.; Fang, J.; Tanaka, S.; Miyamoto, Y.; Akaike, T.; Maeda, H. Pegylated zinc protoporphyrin: a watersoluble heme oxygenase inhibitor with tumor-targeting capacity. Bioconjug. Chem. 2002, 13, 1031-1038.
67. Fang, J.; Sawa, T.; Akaike, T. In vivo antitumor activity of pegylated zinc protoporphyrin: Targeted inhibition of heme oxygenase in solid tumor. Cancer Res. 2003, 63, 3567-3574.
68. Fang, J.; Sawa, T.; Akaike, T.; Greish, K.; Maeda, H. Enhancement of chemotherapeutic response of tumor cells by a heme oxygenase inhibitor, pegylated zinc protoporphyrin. Int. J. cancer 2004, 109, 1-8.
69. Fang, J.; Nakamura, H.; Maeda, H. The EPR effect: Unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Adv. Drug Deliv. Rev. 2011, 63, 136-151.
70. Iyer, A. K.; Greish, K.; Fang, J.; Murakami, R.; Maeda, H. Highloading nanosized micelles of copoly(styrene-maleic acid)-zinc protoporphyrin for targeted delivery of a potent heme oxygenase inhibitor. Biomaterials 2007, 28, 1871-1881.
71. Nakamura, H.; Fang, J.; Gahininath, B.; Tsukigawa, K.; Maeda, H. Intracellular uptake and behavior of two types zinc protoporphyrin (ZnPP) micelles, SMA-ZnPP and PEG-ZnPP as anticancer agents; unique intracellular disintegration of SMA micelles. J. Control. release 2011, 155, 367-375.
72. Maeda, H.; Bharate, G. Y.; Daruwalla, J. Polymeric drugs for efficient tumor-targeted drug delivery based on EPR-effect. Eur. J. Pharm. Biopharm. 2009, 71, 409-419.
73. Herrmann, H.; Kneidinger, M.; Cerny-Reiterer, S.; Rülicke, T.; Willmann, M.; Gleixner, K. V; Blatt, K.; Hörmann, G.; Peter, B.; Samorapoompichit, P.; Pickl, W.; Bharate, G. Y.; Mayerhofer, M.; Sperr, W. R.; Maeda, H.; Valent, P. The Hsp32 inhibitors SMAZnPP and PEG-ZnPP exert major growth-inhibitory effects on CD34+/CD38+ and CD34+/CD38-AML progenitor cells. Curr. Cancer Drug Targets 2012, 12, 51-63.
74. La, P.; Fernando, A. P.; Wang, Z.; Salahudeen, A.; Yang, G.; Lin, Q.; Wright, C. J.; Dennery, P. A. Zinc protoporphyrin regulates cyclin D1 expression independent of heme oxygenase inhibition. J. Biol. Chem. 2009, 284, 36302-36311.
75. Vreman, H. J.; Ekstrand, B. C.; Stevenson, D. K. Selection of metalloporphyrin heme oxygenase inhibitors based on potency and photoreactivity. Pediatr. Res. 1993, 33, 195-200.
76. Vlahakis, J. Z.; Kinobe, R. T.; Bowers, R. J.; Brien, J. F.; Nakatsu, K.; Szarek, W. A. Synthesis and evaluation of azalanstat analogues as heme oxygenase inhibitors. Bioorg. Med. Chem. Lett. 2005, 15, 1457-1461.
77. Morisawa, T.; Wong, R. J.; Bhutani, V. K.; Vreman, H. J.; Stevenson, D. K. Inhibition of heme oxygenase activity in newborn mice by azalanstat. Can. J. Physiol. Pharmacol. 2008, 86, 651-659.
78. Rahman, M. N.; Vukomanovic, D.; Vlahakis, J. Z.; Szarek, W. A.; Nakatsu, K.; Jia, Z. Structural insights into human heme oxygenase-1 inhibition by potent and selective azole-based compounds. J. R. Soc. Interface 2012.
79. Vlahakis, J. Z.; Hum, M.; Rahman, M. N.; Jia, Z.; Nakatsu, K.; Szarek, W. A. Synthesis and evaluation of imidazole-dioxolane compounds as selective heme oxygenase inhibitors: effect of substituents at the 4-position of the dioxolane ring. Bioorg. Med. Chem. 2009, 17, 2461-2475.
80. Vlahakis, J. Z.; Lazar, C.; Roman, G.; Vukomanovic, D.; Nakatsu, K.; Szarek, W. A. Heme oxygenase inhibition by α-(1H-imidazol-1-yl)-ω-phenylalkanes: effect of introduction of heteroatoms in the alkyl linker. ChemMedChem. 2012, 7, 897-902.
81. Salerno, L.; Pittalà, V.; Romeo, G.; Modica, M. N.; Siracusa, M. A.; Di Giacomo, C.; Acquaviva, R.; Barbagallo, I.; Tibullo, D.; Sorrenti, V. Evaluation of novel aryloxyalkyl derivatives of imidazole and 1,2,4-triazole as heme oxygenase-1 (HO-1) inhibitors and their antitumor properties. Bioorg. Med. Chem. 2013, 21, 1-9.
82. Csongradi, E.; Vera, T.; Rimoldi, J. M.; Gadepalli, R. S. V.; Stec, D. E. In vivo inhibition of renal heme oxygenase with an imidazoledioxolane inhibitor. Pharmacol. Res. 2010, 61, 525-530.
83. Willis, D.; Moore, A. R.; Frederick, R.; Willoughby, D. A. Heme oxygenase: A novel target for the modulation of the inflammatory response. Nat. Med. 1996, 2, 87-90.
84. Poss, K. D.; Tonegawa, S. Heme oxygenase 1 is required for mammalian iron reutilization. Proc. Natl. Acad. Sci. U. S. A. 1997, 94, 10919-10924.
85. Kawashima, a. Heme oxygenase-1 deficiency: The first autopsy case. Hum. Pathol. 2002, 33, 125-130.
86. Yamashita, K.; Öllinger, R.; Mcdaid, J.; Sakahama, H.; Wang, H.; Tyagi, S.; Csizmadia, E.; Smith, N. R.; Soares, M. P.; Bach, F. H. Heme oxygenase-1 is essential for and promotes tolerance to transplanted organs. FASEB J. 2006, 20, 1-20.
87. Otterbein, L. E.; Bach, F. H.; Alam, J.; Soares, M.; Tao Lu, H.; Wysk, M.; Davis, R. J.; Flavell, R. A.; Choi, A. M. Carbon monoxide has anti-inflammatory effects involving the mitogenactivated protein kinase pathway. Nat. Med. 2000, 6, 422-428.
88. Lee, T.-S.; Chau, L.-Y. Heme oxygenase-1 mediates the antiinflammatory effect of interleukin-10 in mice. Nat. Med. 2002, 8, 240-246.
89. Morse, D.; Pischke, S. E.; Zhou, Z.; Davis, R. J.; Flavell, R. A.; Loop, T.; Otterbein, S. L.; Otterbein, L. E.; Choi, A. M. K. Suppression of inflammatory cytokine production by carbon monoxide involves the JNK pathway and AP-1. J. Biol. Chem. 2003, 278, 36993-36998.
90. Wang, X. M.; Kim, H. P.; Nakahira, K.; Ryter, S. W.; Choi, A. M. K. The heme oxygenase-1/carbon monoxide pathway suppresses TLR4 signaling by regulating the interaction of TLR4 with caveolin-1. J. Immunol. 2009, 182, 3809-3818.
91. Pae, H.-O.; Oh, G.-S.; Choi, B.-M.; Chae, S.-C.; Kim, Y.-M.; Chung, K.-R.; Chung, H.-T. Carbon monoxide produced by heme oxygenase-1 suppresses T cell proliferation via inhibition of IL-2 production. J. Immunol. 2004, 172, 4744-4751.
92. Liu, Y.; Li, P.; Lu, J.; Xiong, W.; Oger, J.; Tetzlaff, W.; Cynader, M. Bilirubin possesses powerful immunomodulatory activity and suppresses experimental autoimmune encephalomyelitis. J. Immunol. 2008, 181, 1887-1897.
93. Quintana, F. J.; Basso, A. S.; Iglesias, A. H.; Korn, T.; Farez, M. F.; Bettelli, E.; Caccamo, M.; Oukka, M.; Weiner, H. L. Control of T(reg) and T(H)17 cell differentiation by the aryl hydrocarbon receptor. Nature 2008, 453, 65-71.
94. Phelan, D.; Winter, G. M.; Rogers, W. J.; Lam, J. C.; Denison, M. S. Activation of the Ah receptor signal transduction pathway by bilirubin and biliverdin. Arch. Biochem. Biophys. 1998, 357, 155-163.
95. Opitz, C. A.; Litzenburger, U. M.; Sahm, F.; Ott, M.; Tritschler, I.; Trump, S.; Schumacher, T.; Jestaedt, L.; Schrenk, D.; Weller, M.; Jugold, M.; Guillemin, G. J.; Miller, C. L.; Lutz, C.; Radlwimmer, B.; Lehmann, I.; von Deimling, A.; Wick, W.; Platten, M. An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor. Nature 2011, 478, 197-203.
96. Wolf, D.; Wolf, A. M.; Rumpold, H.; Fiegl, H.; Zeimet, A. G.; Muller-Holzner, E.; Deibl, M.; Gastl, G.; Gunsilius, E.; Marth, C. The expression of the regulatory T cell-specific forkhead box transcription factor FoxP3 is associated with poor prognosis in ovarian cancer. Clin. Cancer Res. 2005, 11, 8326-8331.
97. Liu, V. C.; Wong, L. Y.; Jang, T.; Shah, A. H.; Park, I.; Yang, X.; Zhang, Q.; Lonning, S.; Teicher, B. A.; Lee, C. Tumor evasion of the immune system by converting CD4+CD25-T cells into CD4+CD25+ T regulatory cells: Role of tumor-derived TGF-beta. J. Immunol. 2007, 178, 2883-2892.
98. Pae, H.-O.; Oh, G.-S.; Choi, B.-M.; Chae, S.-C.; Chung, H.-T. Differential expressions of heme oxygenase-1 gene in CD25-and CD25+ subsets of human CD4+ T cells. Biochem. Biophys. Res. Commun. 2003, 306, 701-705.
99. Xia, Z.; Zhong, W.; Xu, L.; Sun, J. Heme oxygenase-1-mediated CD4 + CD25 high regulatory T cells suppress allergic airway inflammation. J. Immunol. 2006, 177, 5936-5945.
100. Choi, B.-M.; Pae, H.-O.; Jeong, Y.-R.; Kim, Y.-M.; Chung, H.-T. Critical role of heme oxygenase-1 in Foxp3-mediated immune suppression. Biochem. Biophys. Res. Commun. 2005, 327, 1066-1071.
101. George, J. F.; Braun, A.; Brusko, T. M.; Joseph, R.; Bolisetty, S.; Wasserfall, C. H.; Atkinson, M. A; Agarwal, A.; Kapturczak, M. H. Suppression by CD4+CD25+ regulatory T cells is dependent on expression of heme oxygenase-1 in antigen-presenting cells. Am. J. Pathol. 2008, 173, 154-160.
102. Zelenay, S.; Chora, A.; Soares, M. P.; Demengeot, J. Heme oxygenase-1 is not required for mouse regulatory T cell development and function. Int. Immunol. 2007, 19, 11-18.
103. Andersen, M. H.; Sørensen, R. B.; Brimnes, M. K.; Svane, I. M.; Becker, J. C.; Straten, P. Identification of heme oxygenase-1-specific regulatory CD8 + T cells in cancer patients. J. Clin. Invest. 2009, 119, 27-29.
104. Chauveau, C.; Rémy, S.; Royer, P. J.; Hill, M.; Tanguy-Royer, S.; Hubert, F.-X.; Tesson, L.; Brion, R.; Beriou, G.; Gregoire, M.; Josien, R.; Cuturi, M. C.; Anegon, I. Heme oxygenase-1 expression inhibits dendritic cell maturation and proinflammatory function but conserves IL-10 expression. Blood 2005, 106, 1694-1702.
105. Remy, S.; Blancou, P.; Tesson, L.; Tardif, V.; Brion, R.; Royer, P. J.; Motterlini, R.; Foresti, R.; Painchaut, M.; Pogu, S.; Gregoire, M.; Bach, J. M.; Anegon, I.; Chauveau, C. Carbon monoxide inhibits TLR-induced dendritic cell immunogenicity. J. Immunol. 2009, 182, 1877-1884.
106. Braudeau, C.; Bouchet, D.; Tesson, L.; Iyer, S.; Remy, S.; Buelow, R.; Anegon, I.; Chauveau, C. Induction of long-term cardiac allograft survival by heme oxygenase-1 gene transfer. Gene Ther. 2004, 11, 701-710.
107. Chora, A. A.; Fontoura, P.; Cunha, A.; Pais, T. F.; Cardoso, S.; Ho, P. P.; Lee, L. Y.; Sobel, R. A.; Steinman, L.; Soares, M. P. Heme oxygenase-1 and carbon monoxide suppress autoimmune neuroinflammation. J. Clin. Invest. 2007, 117, 438-447.
108. Kotsch, K.; Martins, P. N. A.; Klemz, R.; Janssen, U.; Gerstmayer, B.; Dernier, A.; Reutzel-Selke, A.; Kuckelkorn, U.; Tullius, S. G.; Volk, H.-D. Heme oxygenase-1 ameliorates ischemia/reperfusion injury by targeting dendritic cell maturation and migration. Antioxid. Redox Signal. 2007, 9, 2049-2063.
109. Weis, N.; Weigert, A.; von Knethen, A.; Bruhe, B. Heme oxygenase-1 contributes to an alternative macrophage activation profile induced by apoptotic cell supernatants. Mol. Biol. Cell 2009, 20, 1280-1288.
110. Sierra-Filardi, E.; Vega, M. A.; Sanchez-Mateos, P.; Corbi, A. L.; Puig-Kroger, A. Heme pxygenase-1 expression in M-CSFpolarized M2 macrophages contributes to LPS-induced IL-10 release. Immunobiology 2010, 215, 788-795.
111. Allavena, P.; Mantovani, A. Immunology in the clinic review series; focus on cancer: tumour-associated macrophages: undisputed stars of the inflammatory tumour microenvironment. Clin. Exp. Immunol. 2012, 167, 195-205.
112. Ostrand-Rosenberg, S.; Sinha, P.; Beury, D. W.; Clements, V. K. Cross-talk between myeloid-derived suppressor cells (MDSC), macrophages, and dendritic cells enhances tumor-induced immune suppression. Semin. Cancer Biol. 2012, 22, 275-281.
113. Gabrilovich, D. I.; Nagaraj, S. Myeloid-derived suppressor cells as regulators of the immune system. Nat. Rev. Immunol. 2009, 9, 162-174.
114. Ghiringhelli, F.; Puig, P. E.; Roux, S.; Parcellier, A.; Schmitt, E.; Solary, E.; Kroemer, G.; Martin, F.; Chauffert, B.; Zitvogel, L. Tumor cells convert immature myeloid dendritic cells into TGFbeta-secreting cells inducing CD4+CD25+ regulatory T cell proliferation. J. Exp. Med. 2005, 202, 919-929.
115. Valenti, R.; Huber, V.; Filipazzi, P.; Pilla, L.; Sovena, G.; Villa, A.; Corbelli, A.; Fais, S.; Parmiani, G.; Rivoltini, L. Human tumorreleased microvesicles promote the differentiation of myeloid cells with transforming growth factor-beta-mediated suppressive activity on T lymphocytes. Cancer Res. 2006, 66, 9290-9298.
116. De Wilde, V.; Van Rompaey, N.; Hill, M.; Lebrun, J. F.; Lemaitre, P.; Lhomme, F.; Kubjak, C.; Vokaer, B.; Oldenhove, G.; Charbonnier, L. M.; Cuturi, M. C.; Goldman, M.; Le Moine, A. Endotoxin-induced myeloid-derived suppressor cells inhibit alloimmune responses via heme oxygenase-1. Am. J. Transplant. 2009, 9, 2034-2047.
117. Rosborough, B. R.; Castellaneta, A.; Natarajan, S.; Thomson, A. W.; Turnquist, H. R. Histone deacetylase inhibition facilitates GMCSF-mediated expansion of myeloid-derived suppressor cells in vitro and in vivo. J. Leukoc. Biol. 2012, 91, 701-709.
118. Burt, T. D.; Seu, L.; Mold, J. E.; Kappas, A.; McCune, J. M. Naive human T cells are activated and proliferate in response to the heme oxygenase-1 inhibitor tin mesoporphyrin. J. Immunol. 2010, 185, 5279-5288.
119. Mougiakakos, D.; Jitschin, R.; Johansson, C. C.; Okita, R.; Kiessling, R.; Le Blanc, K. The impact of inflammatory licensing on heme oxygenase-1-mediated induction of regulatory T cells by human mesenchymal stem cells. Blood 2011, 117, 4826-4835.
120. Ascierto, P. a; Marincola, F. M.; Ribas, A. Anti-CTLA4 monoclonal antibodies: the past and the future in clinical application. J. Transl. Med. 2011, 9, 196.
121. Pedicord, V. A.; Montalvo, W.; Leiner, I. M.; Allison, J. P. Single dose of anti-CTLA-4 enhances CD8+ T-cell memory formation, function, and maintenance. Proc. Natl. Acad. Sci. U. S. A. 2011, 108, 266-271.
122. Brahmer, J. R.; Drake, C. G.; Wollner, I.; Powderly, J. D.; Picus, J.; Sharfman, W. H.; Stankevich, E.; Pons, A.; Salay, T. M.; McMiller, T. L.; Gilson, M. M.; Wang, C.; Selby, M.; Taube, J. M.; Chen, L.; Korman, A. J.; Pardoll, D. M.; Lowy, I.; Topalian, S. L. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J. Clin. Oncol. 2010, 28, 3167-3175.
123. Pardoll, D. M. The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer 2012, 12, 252-264.
124. Schumacher, A.; Wafula, P. O.; Teles, A.; El-Mousleh, T.; Linzke, N.; Zenclussen, M. L.; Langwisch, S.; Heinze, K.; Wollenberg, I.; Casalis, P. A.; Volk, H.-D.; Fest, S.; Zenclussen, A. C. Blockage of heme oxygenase-1 abrogates the protective effect of regulatory T cells on murine pregnancy and promotes the maturation of dendritic cells. PLoS One 2012, 7, e42301.
125. Sorensen, R. B.; Hadrup, S. R.; Svane, I. M.; Hjortso, M. C.; Straten, Thor Straten, P.; Andersen, M. H. Indoleamine 2,3-dioxygenase specific, cytotoxic T cells as immune regulators. Blood, 2011, 117, 220-2210.